VIASKIN Peanut Patch

DBV Technologies reports 296M shares outstanding and 296M voting rights as of March 31, 2026, with updates on VIASKIN® Peanut Patch clinical programs.

DBV Technologies files 2025 annual report disclosing 296M shares outstanding, 295.9M voting rights as VIASKIN Peanut development continues.

DBV Technologies' peanut allergy patch met Phase 3 goals with 46.6% responder rate versus 14.8% placebo, supporting planned 2026 FDA submission.

DBV Technologies announced strong Phase 3 data for VIASKIN® Peanut patch, with 82.8% of treated children showing improved tolerance. FDA submission planned for H1 2026.